{"id":"NCT00251641","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)","officialTitle":"An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09-01","primaryCompletion":"2008-06-01","completion":"2008-06-01","firstPosted":"2005-11-10","resultsPosted":"2009-07-14","lastUpdate":"2017-05-10"},"enrollment":868,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"infliximab","otherNames":["SCH 215596","Remicade"]},{"type":"DRUG","name":"methotrexate","otherNames":["Trexall","Rheumatrex"]}],"arms":[{"label":"Infliximab","type":"EXPERIMENTAL"},{"label":"Methotrexate","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment of moderate to severe psoriasis in adults who were diagnosed with moderate to severe plaque-type psoriasis for at least 6 months prior to screening (subjects with concurrent psoriatic arthritis may also be enrolled).","primaryOutcome":{"measure":"Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16.","timeFrame":"16 weeks","effectByArm":[{"arm":"Infliximab","deltaMin":0.78,"sd":null},{"arm":"Methotrexate","deltaMin":0.42,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21910713"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":649},"commonTop":["NASOPHARYNGITIS","HEADACHE","INFUSION RELATED REACTION","ARTHRALGIA","FATIGUE"]}}